Based on the wide array of cellular and transcriptional pro-oncogenic processes regulated by PRMT5, a number of inhibitors have been developed and tested in preclinical studies across several tumor types, showing promising tumor-suppressive effects as a single agent or in combination with targeted therapeutics or chemotherapy [40]. This evidence concerns the gene PRMT5 and neoplasm.